Trials / Completed
CompletedNCT02842359
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
Efficacy Evaluation of Metabolic, Anti-inflammatory, and Antioxidative Factors of Irbesartan/Atorvastatin Fixed-dose Combination in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension, With Adequately Controlled Blood Glucose Levels
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 19 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
Primary Objective: To evaluate the effect of irbesartan/atorvastatin fixed-dose combination comparing to each irbesartan and atorvastatin on flow mediated dilation change in type 2 diabetic patients diagnosed with hyperlipidemia, hypertension. Secondary Objective: To evaluate efficacy of blood pressure and hyperlipidemic factors of irbesartan/atorvastatin fixed-dose combination in type 2 diabetic patients diagnosed with hyperlipidemia and hypertension, with adequately controlled blood glucose levels in groups.
Detailed description
The total study duration per patient is up to maximum of 7 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irbesartan/atorvastatin fixed dose combination | Pharmaceutical form:Tablet Route of administration: Oral |
| DRUG | Irbesartan SR47436 | Pharmaceutical form:Tablet Route of administration: Oral |
| DRUG | Atorvastatin | Pharmaceutical form:Tablet Route of administration: Oral |
Timeline
- Start date
- 2016-08-23
- Primary completion
- 2018-04-19
- Completion
- 2018-04-19
- First posted
- 2016-07-22
- Last updated
- 2022-04-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02842359. Inclusion in this directory is not an endorsement.